XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Shareholders' Equity (Deficit) (Tables)
6 Months Ended
Jun. 30, 2024
Shareholders’ Equity (Deficit) [Line Items]  
Schedule of Company Obligated to Issue Shares As of June 30, 2024 and December 31, 2023, the Company was obligated to issue the following shares:
   June 30, 2024   December 31, 2023 
   Amount   Shares   Amount   Shares 
Shares issuable to employees and consultants  $50,874    752,651   $261,682    2,356,188 
Shares issuable to independent directors   60,000    1,224,492    20,000    408,164 
   $110,874    1,977,143   $281,682    2,764,352 

 

Schedule of Financial Statements with Respect to the EIPs Amounts recognized in the financial statements with respect to the EIPs in the three and six months ended June 30, 2024 and 2023 were as follows:
   Three Months Ended June 30,   Six Months Ended June 30, 
   2024   2023   2024   2023 
Total cost of share-based payment plans during the period  $87,035   $76,402   $123,021   $159,353 
Amounts capitalized in deferred equity compensation during period  $
   $
   $
   $
 
Amounts written off from deferred equity compensation during period  $
   $
   $57,147   $
 
Amounts charged against income for amounts previously capitalized  $
   $5,204   $
   $10,354 
Amounts charged against income, before income tax benefit  $87,035   $81,606   $180,168   $169,707 
Amount of related income tax benefit recognized in income  $
   $
   $
   $
 
Stock Warrants [Member]  
Shareholders’ Equity (Deficit) [Line Items]  
Schedule of Stock Warrants Transactions involving our stock warrants during the six months ended June 30, 2024 and 2023 are summarized as follows:
   2024   2023 
       Weighted       Weighted 
       Average       Average 
       Exercise       Exercise 
   Number   Price   Number   Price 
Outstanding at beginning of the period   77,414,648   $0.20    68,109,094   $0.22 
Granted during the period   19,992,346   $0.07    10,619,698   $0.10 
Exercised during the period   
   $
    
   $
 
Expired during the period   (1,342,402)  $(0.28)   (3,662,333)  $(0.25)
Outstanding at end of the period   96,064,592   $0.18    75,066,459   $0.21 
                     
Exercisable at end of the period   96,064,592   $0.18    75,066,459   $0.21 
                     
Weighted average remaining life   3.3    years    2.2    years 
Schedule of Financial Statements with Respect to the EIPs The following table summarizes information about the Company’s stock warrants outstanding as of June 30, 2024:
Warrants Outstanding   Warrants Exercisable 
        Weighted-             
        Average   Weighted-       Weighted- 
        Remaining   Average       Average 
Exercise   Number   Contractual   Exercise   Number   Exercise 
Prices   Outstanding   Life (years)   Price   Exercisable   Price 
$ 0.0001 to 0.09    40,362,039    5.0   $0.06    40,362,039   $0.06 
$0.10 to 0.24    25,875,536    2.8   $0.16    25,875,536   $0.16 
$0.25 to 0.49    26,867,093    1.3   $0.31    26,867,093   $0.31 
$0.50 to 1.05    2,959,924    2.0   $0.68    2,959,924   $0.68 
$0.05 to 1.00    96,064,592    3.3   $0.18    96,064,592   $0.18 
Schedule of Aggregate Grant Date Fair Value The fair value of the warrants was calculated using the following range of assumptions:
   2024  2023
Pricing model utilized  Binomial Lattice  Binomial Lattice
Risk free rate range  3.97% to 4.20%  3.60% to 4.27%
Expected life range (in years)  5.00 years to 10.00 years  0.28 years to 5.00 years
Volatility range  139.73% to 173.25%  126.30% to 141.2%
Dividend yield  0.00%  0.00%
Expected forfeiture  33.00%  20.00%
Stock Options [Member]  
Shareholders’ Equity (Deficit) [Line Items]  
Schedule of Stock Options The following table summarizes stock option activity as of and for the six months ended June 30, 2024 and 2023:
   2024   2023 
       Weighted       Weighted 
       Average       Average 
       Exercise       Exercise 
Stock options  Number   Price   Number   Price 
Outstanding at beginning of period   5,093,738   $0.16    5,222,982   $0.20 
Granted during the period   4,804,974   $0.06    93,750   $0.08 
Exercised during the period   
   $
    
   $
 
Forfeited during the period   (449,982)  $(0.21)   (450,000)  $(0.16)
Outstanding at end of period   9,448,730   $0.10    4,866,732   $0.17 
                     
Options exercisable at period-end   7,202,896   $0.11    3,110,815   $0.20 

 

Schedule of Fair Value of Options Granted The fair value of options granted for the six months ended June 30, 2024 and 2023 was calculated using the following range of assumptions:
   2024  2023
Pricing model utilized  Binomial Lattice  Binomial Lattice
Risk free rate range  4.20%  3.48%
Expected life range (in years)  10.00 years  10.00 years
Volatility range  173.09% to 173.25%  145.03%
Dividend yield  0.00%  0.00%
Expected forfeiture  30.00%  30.00%
Schedule of Stock Grant Activity The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the six months ended June 30, 2024 and 2023:
   2024   2023 
       Weighted       Weighted 
       Average       Average 
       Grant Date       Grant Date 
Stock options  Shares   Fair Value   Shares   Fair Value 
Nonvested options at beginning of period   1,073,084   $0.06    2,260,417   $0.08 
Granted   4,804,974   $0.04    93,750   $0.05 
Vested   (3,582,224)  $(0.04)   (298,250)  $(0.12)
Forfeited   (50,000)  $(0.08)   (300,000)  $(0.09)
Nonvested options at end of period   2,245,834   $0.05    1,755,917   $0.07 

 

Stock Grants [Member]  
Shareholders’ Equity (Deficit) [Line Items]  
Schedule of Stock Grant Activity The following table summarizes stock grant activity as of and for the six months ended June 30, 2024 and 2023:
   2024   2023 
       Weighted       Weighted 
       Average       Average 
       Grant Date       Grant Date 
Stock Grants  Shares   Fair Value   Shares   Fair Value 
Nonvested grants at beginning of period   1,484,488   $0.05    1,651,435   $0.05 
Granted   
   $
    160,944   $0.09 
Vested   (821,328)  $(0.05)   (981,584)  $(0.05)
Forfeited   (50,000)  $(0.12)   (15,000)  $(0.26)
Nonvested grants at end of period   613,160   $0.05    815,795   $0.05